These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 33241214)
1. RNAi technology targeting the Parker Kerrigan BC; Ledbetter D; Kronowitz M; Phillips L; Gumin J; Hossain A; Yang J; Mendt M; Singh S; Cogdell D; Ene C; Shpall E; Lang FF Neurooncol Adv; 2020; 2(1):vdaa132. PubMed ID: 33241214 [TBL] [Abstract][Full Text] [Related]
2. Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma. Wu Y; Jin W; Wang Q; Zhou J; Wang Y; Tan Y; Cui X; Tong F; Yang E; Wang J; Kang C Mol Ther; 2021 Nov; 29(11):3305-3318. PubMed ID: 34274537 [TBL] [Abstract][Full Text] [Related]
3. HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion. Li T; Mehraein-Ghomi F; Forbes ME; Namjoshi SV; Ballard EA; Song Q; Chou PC; Wang X; Parker Kerrigan BC; Lang FF; Lesser G; Debinski W; Yang X; Zhang W Mol Ther; 2022 Apr; 30(4):1610-1627. PubMed ID: 35151844 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and Molecular Characteristics of Bae H; Lee B; Hwang S; Lee J; Kim HS; Suh YL Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255255 [TBL] [Abstract][Full Text] [Related]
5. A metabolic function of FGFR3-TACC3 gene fusions in cancer. Frattini V; Pagnotta SM; Tala ; Fan JJ; Russo MV; Lee SB; Garofano L; Zhang J; Shi P; Lewis G; Sanson H; Frederick V; Castano AM; Cerulo L; Rolland DCM; Mall R; Mokhtari K; Elenitoba-Johnson KSJ; Sanson M; Huang X; Ceccarelli M; Lasorella A; Iavarone A Nature; 2018 Jan; 553(7687):222-227. PubMed ID: 29323298 [TBL] [Abstract][Full Text] [Related]
7. FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium. Best SA; Harapas CR; Kersbergen A; Rathi V; Asselin-Labat ML; Sutherland KD Oncogene; 2018 Nov; 37(46):6096-6104. PubMed ID: 29991799 [TBL] [Abstract][Full Text] [Related]
8. Extra-CNS and dural metastases in Kleinschmidt-DeMasters BK; Gilani A Neurooncol Pract; 2022 Oct; 9(5):449-455. PubMed ID: 36134017 [TBL] [Abstract][Full Text] [Related]
9. Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability. Wang CG; Peiris MN; Meyer AN; Nelson KN; Donoghue DJ Oncotarget; 2023 Feb; 14():133-145. PubMed ID: 36780330 [TBL] [Abstract][Full Text] [Related]
10. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions. Mata DA; Benhamida JK; Lin AL; Vanderbilt CM; Yang SR; Villafania LB; Ferguson DC; Jonsson P; Miller AM; Tabar V; Brennan CW; Moss NS; Sill M; Benayed R; Mellinghoff IK; Rosenblum MK; Arcila ME; Ladanyi M; Bale TA Acta Neuropathol Commun; 2020 Nov; 8(1):186. PubMed ID: 33168106 [TBL] [Abstract][Full Text] [Related]
11. Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling. Nelson KN; Meyer AN; Wang CG; Donoghue DJ Oncotarget; 2018 Sep; 9(76):34306-34319. PubMed ID: 30344944 [TBL] [Abstract][Full Text] [Related]
12. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions. Tamura R; Yoshihara K; Saito T; Ishimura R; MartÃnez-Ledesma JE; Xin H; Ishiguro T; Mori Y; Yamawaki K; Suda K; Sato S; Itamochi H; Motoyama T; Aoki Y; Okuda S; Casingal CR; Nakaoka H; Inoue I; Verhaak RGW; Komatsu M; Enomoto T Oncogenesis; 2018 Jan; 7(1):4. PubMed ID: 29358619 [TBL] [Abstract][Full Text] [Related]
13. Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives. Picca A; Sansone G; Santonocito OS; Mazzanti CM; Sanson M; Di Stefano AL Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067258 [TBL] [Abstract][Full Text] [Related]
15. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling. Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413 [TBL] [Abstract][Full Text] [Related]
16. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples. Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669 [TBL] [Abstract][Full Text] [Related]
17. RT-PCR assay to detect Priesterbach-Ackley LP; van Kuik J; Tops BBJ; Lasorella A; Iavarone A; van Hecke W; Robe PA; Wesseling P; de Leng WWJ Neurooncol Pract; 2024 Apr; 11(2):142-149. PubMed ID: 38496910 [TBL] [Abstract][Full Text] [Related]
18. Development of a degrader against oncogenic fusion protein FGFR3-TACC3. Shibata N; Cho N; Koyama H; Naito M Bioorg Med Chem Lett; 2022 Mar; 60():128584. PubMed ID: 35085722 [TBL] [Abstract][Full Text] [Related]
19. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896 [TBL] [Abstract][Full Text] [Related]
20. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. Parker BC; Annala MJ; Cogdell DE; Granberg KJ; Sun Y; Ji P; Li X; Gumin J; Zheng H; Hu L; Yli-Harja O; Haapasalo H; Visakorpi T; Liu X; Liu CG; Sawaya R; Fuller GN; Chen K; Lang FF; Nykter M; Zhang W J Clin Invest; 2013 Feb; 123(2):855-65. PubMed ID: 23298836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]